医学
神经氨酸酶
神经氨酸酶抑制剂
病毒学
病毒
药理学
内科学
2019年冠状病毒病(COVID-19)
疾病
传染病(医学专业)
作者
Masafumi Seki,Yuko Sakai‐Tagawa,Atsuhiro Yasuhara,Yuji Watanabe
出处
期刊:IDCases
[Elsevier BV]
日期:2019-01-01
卷期号:18: e00650-e00650
被引量:8
标识
DOI:10.1016/j.idcr.2019.e00650
摘要
We describe two adults with A/H3N2 influenza with (patient 1), and without (patient 2) polymerase acidic (PA) subunit I38 T substitution during the same season. Patient 1 had a reduced clinical response to baloxavir, a cap-dependent endonuclease inhibitor (CEI), but was cured by peramivir, a neuraminidase inhibitor. Baloxavir was clinically effective for patient 2, for whom peramivir had been ineffective. Susceptibility to baloxavir can be decreased by a PA unit mutation, but response to treatment can be increased by switching and/or combination with a neuraminidase inhibitor, even though CEI are clinically effective against influenza in adults.
科研通智能强力驱动
Strongly Powered by AbleSci AI